Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme

ClinicalTrials.gov ID: NCT00458601

Public ClinicalTrials.gov record NCT00458601. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Study identification

NCT ID
NCT00458601
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Celldex Therapeutics
Industry
Enrollment
82 participants

Conditions and interventions

Interventions

  • CDX-110 with GM-CSF Drug
  • Temozolomide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2007
Primary completion
Oct 31, 2010
Completion
Apr 30, 2016
Last update posted
Jan 15, 2018

2007 – 2016

United States locations

U.S. sites
34
U.S. states
15
U.S. cities
25
Facility City State ZIP Site status
Celldex Investigational Site Orange California 92868
Celldex Investigational Site San Francisco California 94143-0622
Celldex Investigational Site San Francisco California 94143
Celldex Investigational Site Stanford California 94305-5826
Celldex Investigational Site Stanford California 94305
Celldex Investigational Site New Haven Connecticut 06510
Celldex Investigational Site New Haven Connecticut 06519
Celldex Investigational Site New Haven Connecticut 06520
Celldex Investigational Site Gainesville Florida 32610-0277
Celldex Investigational Site Chicago Illinois 60611
Celldex Investigational Site Evanston Illinois 60201
Celldex Investigational Site Boston Massachusetts 02115
Celldex Investigational Site Lansing Michigan 48912
Celldex Investigational Site Saginaw Michigan 48601
Celldex Investigational Site Saginaw Michigan 48604
Celldex Investigational Site Hackensack New Jersey 07601
Celldex Investigational Site Amherst New York 14226
Celldex Investigational Site New York New York 10032
Celldex Investigational Site New York New York 10065
Celldex Investigational Site Durham North Carolina 27710
Celldex Investigational Site Cincinnati Ohio 45219
Celldex Investigational Site Cincinnati Ohio 45267-0502
Celldex Investigational Site Cincinnati Ohio 45267-0769
Celldex Investigational Site Cleveland Ohio 44106
Celldex Investigational Site Cleveland Ohio 44195
Celldex Investigational Site Orange Ohio 44122
Celldex Investigational Site West Chester Ohio 45069-6542
Celldex Investigational Site Westlake Ohio 44145
Celldex Investigational Site Philadelphia Pennsylvania 19104
Celldex Investigational Site Houston Texas 77030
Celldex Investigational Site San Antonio Texas 78229
Celldex Investigational Site Salt Lake City Utah 84112
Celldex Investigational Site Charlottesville Virginia 22908
Celldex Investigational Site Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00458601, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 15, 2018 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00458601 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →